Low-Density Lipoprotein e (LDL) Distribution Shown by ^99mTechnetium-LDL Imaging in Patients with Myeloproliferative Diseases

Vallabhajosula, Shankar; Gilbert, Harriet S.; Goldsmith, Stanley J.; Paidi, Michael; Hanna, Magdy M.; Ginsberg, Henry N.

doi:10.7326/0003-4819-110-3-208

Cited by 20 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In myeloproliferative diseases, on the other hand, decreased LDL is associated with increased clearance of LDL (Ginsberg, Le, Gilbert, Le, & Brown, 1986;Vallabhajosula et al, 1989). Lymphomas, leukemia, and other malignancies have increased levels and increased activity of LDL receptors, which avidly bind and take up LDL, thus reducing their concentra tion.…”

Section: Mechanisms Underlying Hypocholesterolemiamentioning

confidence: 99%

Hypocholesterolemia, hypolipoproteinemia, and risk of death.

Verdery¹

1997

Lipids, Health, and Behavior.

View full text Add to dashboard Cite

Although it is well established that high levels of cholesterol and certain lipoproteins are strongly associated with increased risk for coronary artery disease, cerebrovascular disease, and death from myocardial infarction and stroke, the association of low levels of cholesterol and certain lipoproteins with increased prevalence of other diseases and risk of death from these diseases has been equally well established. The earliest reports of association of low cholesterol levels with disease, particularly malnutrition and cancer, are from the 1930s (G. L. Muller, 1930). Reports from the 1940s describe the association between low cholesterol levels and acute febrile illnesses (Nishita, 1941).Since these early studies on low blood lipid levels in chronic and acute disease, there have been significant changes in both our understanding of the biochemistry of lipids and lipoproteins and the methodology used to measure blood lipids and lipoproteins. Initially, blood lipid levels measured included only total cholesterol, triglyceride, and phospholipid. In the 1 9 5 0 ~~ lipoproteins were discovered to be the carriers of these lipids, and measurements of specific lipoproteins, primarily chylomicrons, very low density lipoproteins (VLDLs), low density lipoproteins (LDLs), and high density lipoproteins (HDLs), became necessary to understand the characteristics of dyslipoproteinemias. More recently, the proteins associated with lipoproteins, apolipoproteins, have been exhaustively studied. Each lipoprotein species has specific apolipoproteins that are important structural elements and help regulate the metabolism of the lipids that are carried.Careful metabolic studies of synthesis and turnover rates of apolipoproteins have shown that to a great extent, levels of cholesterol and other lipids and of specific lipoproteins are regulated by synthesis and turnover rates of associated apolipoproteins and levels of certain enzymes, including lipoprotein lipase (LPL), hepatic triglyceride lipase (WGL), lecithin cho-This work was supported in part by National Institute on Aging Grant SERCA KOl-AGO0414 and the Arizona Center on Aging,

show abstract

Section: Mechanisms Underlying Hypocholesterolemiamentioning

confidence: 99%

Hypocholesterolemia, hypolipoproteinemia, and risk of death.

Verdery¹

1997

Lipids, Health, and Behavior.

View full text Add to dashboard Cite

show abstract

“…6,7 Accordingly, we focused on serum albumin and cholesterol levels because of their known susceptibility to the effects of myelofibrosis-associated inflammatory cytokines and their global applicability. [8][9][10][11] The phenomenon of markedly decreased cholesterol levels in myelofibrosis has long been recognized, 12 and its prognostic relevance has been highlighted in multiple abstracts. [13][14][15][16] More recent reports have suggested a similar scenario with serum albumin.…”

Section: Introductionmentioning

confidence: 99%

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels

Tefferi¹,

Nicolosi²,

Penna³

et al. 2018

Blood Advances

View full text Add to dashboard Cite

show abstract

“…In PV several studies have demonstrated reduced serum levels of total-, HDL-and LDLcholesterol, and LDL degradation is increased via both LDL-receptor and non-receptor pathways (13)(14)(15). The spleen and bone marrow have been shown to be the major sites of LDL catabolism in PV in contrast to healthy controls in which LDL is primarily degraded in the liver (16). Nevertheless, it has recently been shown in patients with familial hypercholesterolaemia that LDL receptor activity is not a major determinant of Lp(a) plasma levels (17).…”

mentioning

confidence: 99%